A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
Trials
; 18(1): 394, 2017 08 29.
Article
in En
| MEDLINE
| ID: mdl-28851403
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rectal Neoplasms
/
Magnetic Resonance Imaging
/
Adenocarcinoma
/
Neoadjuvant Therapy
/
Chemoradiotherapy, Adjuvant
Type of study:
Clinical_trials
/
Guideline
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Trials
Journal subject:
MEDICINA
/
TERAPEUTICA
Year:
2017
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
United kingdom